FDA updates TYSABRI(R) (NATALIZUMAB) label to include anti-JCV antibody status as a PML risk factor
20 January 2012 | By Biogen Idec and Elan Corporation, plc
The U.S. FDA has approved a product label change for TYSABRI...
List view / Grid view
20 January 2012 | By Biogen Idec and Elan Corporation, plc
The U.S. FDA has approved a product label change for TYSABRI...
4 January 2012 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into an exclusive, worldwide option and collaboration agreement...
26 October 2011 | By Biogen Idec
Positive top-line results announced...
21 October 2011 | By Biogen Idec
Phase 3 clinical trial demonstrated significant clinical effects...
6 September 2011 | By Biogen Idec
Biogen Idec will acquire 100% of Dompé shares in its joint ventures in both Italy and Switzerland...
9 August 2011 | By Abbott
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial...
27 July 2011 | By Biogen Idec
Biogen Idec has strengthened MS ActiveSource...
3 July 2011 | By Biogen Idec
Results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach...
7 June 2011 | By Biogen Idec
Biogen Idec announced that the European Commission has granted approval to AVONEX PEN...
20 May 2011 | By Biogen Idec
Biogen Idec announced that FAMPYRA(R) (prolonged-release fampridine tablets) has been granted a positive opinion for conditional approval from the EMA's CHMP...
9 May 2011 | By Biogen Idec
The EMA Pediatric Committee has adopted an opinion agreeing to the pediatric investigational plan...
19 April 2011 | By Biogen Idec
Genentech, and Biogen Idec announced today that the FDA approved Rituxan® (rituximab)...